Bright Minds Biosciences Inc. (DRUG) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
1500 – 1055 West Georgia Street
New York City, BC V6E 4N7
Canada
Phone
647 407 2515
Website
Sector
Healthcare
Industry
Biotechnology
Employees
26
First IPO Date
March 22, 2021
| Name | Title | Pay | Year Born |
| Ian McDonald | Co-Founder, Chief Executive Officer, President & Director | 0 | 1988 |
| Ryan E. S. K. Cheung | CFO & Corporate Secretary | 94,705 | 1978 |
| Stephen D. Collins | Chief Medical Officer | 227,375 | 1953 |
| Jan Torleif Pedersen | Chief Science Officer & Director | 515,517 | 1965 |
| Alex Vasilkevich | Chief Operating Officer & Senior Scientific Officer | 0 | 1989 |
| Emer Leahy | Consultant | 0 | 1967 |
Bright Minds Biosciences Inc. is a preclinical biotechnology firm dedicated to creating serotonin-based therapies. Its primary goal is to enhance the well-being of individuals suffering from severe and life-altering conditions. The company's development pipeline includes selective agonists for the 5-HT2C, 5-HT2A, and combined 5-HT2C/A serotonin receptors, which are being explored for potential treatments in epilepsy, pain management, and neuropsychiatric disorders. Bright Minds maintains strategic collaborations with the National Institutes of Health (NIH) for epilepsy research, the University of Texas Medical Branch (UTMB) for impulse control disorders like binge eating, and the Medical College of Wisconsin. The company, incorporated in 2019, operates from its headquarters in Vancouver, Canada.